MIA's Dermatology services expanded
27 May 2016
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia. We now have five specialist dermatologists consulting from the Poche Centre:
- Associate Professor Pascale Guitera
- Dr Linda Martin
- Dr Erin Mullan
- Dr Hsien Herbert Chan
- Dr Annika Smith
Our areas of expertise include:
- Diagnosis of difficult melanocytic lesions
- Dysplastic naevus syndrome
- Lentigo maligna
- Amelanotic melanoma
- Nail pigmentation
- Mucosal pigmentation
- Management of cutaneous side effects of systemic targeted and immunotherapies for metastatic melanoma
- Pigmented lesions and melanoma in pregnancy
- Patient education on skin cancer prevention and melanoma patient support group
We also have state-of-the-art non-invasive diagnostic technology including:
- Advanced dermoscopy
- In-vivo confocal reflectance microscopy
- Total body photography
- Sequential dermoscopic imaging
- Optical coherence tomography
Contact Dermatology at MIA:
Suite 8, Level 3
The Poche Centre
40 Rocklands Rd
Wollstonecraft NSW 2065
T: 02 9911 7277
F: 02 9922 7220
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.